The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework
This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
1. Exemestane administered as adjuvant therapy to breast cancer patients who have completed 5 yrs of Tamoxifen extended disease free survival, recurrence free survival and overall survival.2. Exemestane after Tamoxifen now repesents an alternative standard of care for appropriate patien...
1. Health Canada has issued a warning to physicians regarding potential bowel toxicity in patients treated with Rituxan.2. 47 cases of bowel obstruction and 37 cases of bowel perforation have been reported in 730,000 patient exposures to Rituxan.
1. IMRT represents a potential advance in the radiation therapy of prostate cancer.2. Because greater use of IMRT likely would decrease the frequency of radical prostatectomies, urologists have begun to initiate their own programs in IMRT, representing a potential complicated interest between financial...
1. Patients with atrial fibrillation, deep venous thrombosis, and pulmonary emboli can require long-term anticoagulation.2. No effective oral anticoagulant is available in the United States that does not require frequent monitoring.3. Rivaroxaban may fill this unmet need.
1. Tarceva has been approved for the treatment of non-small cell lung cancer (NSCLC) in the United States.2. In the UK, the National Institute for Health and Clinical Excellence has stated that Tarceva is not cost effective and is no more effective for treating lung cancer than other...
1. Whole brain radiation therapy (WBRT) remains the standard of care for patients with multiple brain metastases from solid tumors.Xcitirin (Motexafin gadolinium) combined with whole brain radiation therapy prolonged time to neurologic progression in non-small cell lung cancer (NSCLC) patients...
1. Gleevec previously was FDA approved for the therapy of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).2. The FDA now has approved five additional indications for Gleevec including dermatofibrosarcoma protuberans, Ph chromosome positive ALL, certain forms of myelodysplasia,...
1. Small cell lung cancer comprises 15-20% of lung cancers diagnosed in the United States2. Although multiple newer chemotherapy agents (Irinotecan, Topotecan) have demonstrated activity in this disease, there has been no advance in chemotherapy in more than a decade that has improved outcome.3. The...